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Abstract
Our ability to successfully intervene in disease processes is dependent on definitive diagnosis. In the case of autoimmune
disease, this is particularly challenging because progression of disease is lengthy and multifactorial. Here we show the first
chronological compendium of transcriptional and cellular signatures of diabetes in the non-obese diabetic mouse. Our data
relates the immunological environment of the islets of Langerhans with the transcriptional profile at discrete times. Based
on these data, we have parsed diabetes into several discrete phases. First, there is a type I interferon signature that precedes
T cell activation. Second, there is synchronous infiltration of all immunological cellular subsets and a period of control.
Finally, there is the killing phase of the diabetogenic process that is correlated with an NF-kB signature. Our data provides
a framework for future examination of autoimmune diabetes and its disease progression markers.
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Introduction
T1D is a T-cell dependent autoimmunity directed against the b-
cells of the pancreatic islets of Langerhans, a process where
autoreactive CD4+ T cells are directed to antigens of the b-cells[1–
4]. The most important genetic determinant of T1D incidence in
both humans and mice is the major histocompatibility complex
(MHC) [5,6]. Despite the strong genetic component of pre-
disposition to disease, concordance between monozygotic twins is
approximately 50% [1,7]. Beside the interplay of genes and
environment in the induction of T1D, there are complex
interactions between different immune system cells that determine
the outcome of disease [8].
Transcriptional profiling permits an unbiased examination on
a genome-wide scale. Thus, it is a powerful tool for analyzing
complex problems like T1D. Examination of islets of Langerhans,
islet infiltrating leukocytes, and pancreatic lymph nodes has been
conducted following several genetic, biological or chemical
manipulations[9–14]. Several important findings have come from
these types of studies. Global expression patterns distinguish
destructive versus innocuous inflammatory responses of islet
infiltrating leukocytes [9]. Chemically induced diabetes led to
upregulation of inflammatory genes with an interferon-c (IFN-c)
signature in islets of Langerhans [11]. The balance between
pancreatic destruction and repair was detected by examining
microarrays from T cell-receptor (TCR) transgenic NOD mice
[13]. Type I interferon inducible genes were detected in pancreatic
lymph node CD4+ T cells isolated from TCR transgenic mice
[14]. Transfer of diabetogenic T cells from TCR transgenic mice
induced an interferon signature that correlated with amplification
of the autoimmune process [12]. Finally, the genetic programs that
led to development of endocrine pancreas were examined using
global transcriptional analysis [10]. Despite these many studies,
a coherent view of the disease development and corresponding
sequence of inflammatory and developmental events in the context
of the spontaneous diabetes is lacking to this date.
A challenge of examining an inflamed islet of Langerhans is the
diversity of cell types in the sample and the ability to reliably detect
changes in levels of expression. Technological improvements in
automation, computation, and reduced cost have allowed an
expansion of reliable data gathering, annotation, and distillation
using microarray technology. The advent of carefully curated
resources such as the Immunological Genome Project provide
a framework for identifying genes related to specific cell types [15].
The increase in publicly available and user-friendly resources for
microarray data analysis also permits reproducible examination of
larger data sets [16]. We have leveraged the power of these
available resources to generate a dataset identifying the key
signatures of progression of T1D in NOD mice.
Here we present the first chronological examination of the
transcriptional landscape of T1D progression in the NOD mouse
from 2 wks of age until diabetes (,20–30 wks). Several striking
results were obtained from the dataset. First, infiltrating myeloid
cells begin to populate the islets of Langerhans as early as 4 wks of
age. This occurred at a time where the islet was still developing, as
determined by signatures of cell cycle and development. Next,
a type I interferon signature was detected between 4 and 6 wks of
age. This is followed by infiltration of islets by all major leukocyte
subsets and T cell activation at 8–12 wks of age. Following full
immunological activation, there was a progressive enhancement of
inflammatory signatures, culminating in the destruction of the islet
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of Langerhans. This data and its analysis provide a framework for
the study of islets of Langerhans and inflammatory responses
during the progression of T1D.
Results
Examination of Islets of Langerhans Reveals a Progressive
Entry of Leukocytes Subsets Throughout Diabetogenesis
Islets of Langerhans were isolated, purified, and then examined
by fluorescence microscopy and flow cytometry at ages ranging
from 2 wks up to newly diabetic. Our goal was to identify changes
in leukocyte infiltration, changes in adhesion molecules, and
immunoglobulin (Ig) deposition on b-cells (Fig. 1).
At 2 wks of age, islets showed no signs of pathology and no
detectable lymphocytes. The earliest time point where lympho-
cytes were identified inside islets occurred at 4 wks of age. CD4+ T
cells were found in ,10% of the islets in close apposition to the
islet resident CD11c+ cells (Fig. 1A–B). The resident
CD11c+CD45+ cells are the intra-islet myeloid cell found in all
strains of mice (reviewed in [17]). CD8+ T cells and B cells were
rarely identified. In control mice, lymphocytes were not detected
inside the islets, only an occasional one was found inside the blood
vessels (see below for control information). In 4 wk old NOD mice,
the islet distribution of the adhesion molecules ICAM-1 and
VCAM-1 showed the profile of a non-inflamed state [12]. ICAM-
1 was only found weakly expressed in the endothelium and
VCAM-1 was absent (Fig. 1B).
In 6 wk old NOD mice, CD4+ T cells were found in , 1/3rd of
the islets, at a median of 3 cells per islet, and always contacting the
islet CD11c+ cells (the number ranged from ,1 to 55 leukocytes
per islet; Fig. 1B–C). Low numbers of CD8+ T cells also were
found while B cells represented a minor component (Fig. 1C). At
about this time, many of the intra-islet vessels had higher ICAM-1
expression throughout most of the vessel wall, and about 10%
showed VCAM-1 expression (Fig. 1B). These changes in adhesion
molecules have been related to the entrance of diabetogenic T cells
[12,18]. IgG deposition was found on the b-cells in many of the
islets (Fig. 1B). The islets of normal mice never showed deposition
of IgG suggesting the presence of NOD-specific autoantibodies.
Major islet changes were found at 8 wks of age. The total
number of leukocytes rose ,7-fold, from ,2.7% to 18% of the
total islet cellularity (Fig. 1C). CD4+ T cells and CD8+ T cells were
found in about half of the islets but B cells only in a limited
number, about 10% (Fig. 1B). There was also an increase in the
number of CD11c+ cells at this stage (Fig. 1C). We found increased
expression of ICAM-1, even on the b-cells, VCAM-1 expression
on the vessels, and IgG deposition on the b-cells (Fig. 1B). At
12 wks of age, peri-insulitis, a leukocytic lesion on the pole of the
islets, was evident in some islets (Fig. 1A). By 18 wks, islets were
heavily infiltrated making quantification difficult (Fig. 1).
Figure 1. Examination of NOD islets throughout diabetogenesis. (A) Islets of Langerhans were isolated from NOD mice at the indicated ages
and stained for blood vessels (PECAM-1), intra islet myeloid cells (CD11c), and T cell (CD4). Shown are representative images obtained from a pool of 6
mice per age from two independent experiments. Insets show contacts between intraislet myeloid cells and T cells. White bars represent 50 mm. (B)
Islets were isolated and stained for the indicated markers and then scored for presence or absence of staining. Bars represent mean+/2S.D. of the
percentage of marker positive islets of Langerhans obtained from a pool of 6 mice per group from two independent experiments. (C) Islets of
Langerhans were dispersed and cells were examined by flow cytometry for the indicated cell surface markers. Bars represent the mean+/2S.D. of the
percentage of total islet cells identified in two independent experiments per age. Results were obtained from a pool of 8 to 10 mice per group.
doi:10.1371/journal.pone.0059701.g001
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Thus, between 4–6 wks the islets of Langerhans showed the first
signs of pathology with the entrance of T cells and signs of islet
reactivity. Starting at,8 wks there was a progressive infiltration of
all major leukocyte subsets and signs of inflammatory marker
expression. The same biological replicates that were interrogated
by microscopy were analyzed for their transcriptional expression
profiles as detailed below.
Assembling the Compendium of Transcriptional Profiles
in the Context of Islet/Diabetes Development
To perform chronological analysis of the transcriptional profile,
the NOD strain was compared with several control strains. Islet
RNA was extracted from 3–6 replicates for each of seven time
points along the lifetime of NOD mice (2, 4, 6, 8, 12, 18 wks and
up to diabetics at ,20 wks) and compared to 6 replicates of 3
control strains. NOD.Rag12/2 mice at 2 and 6 wks of age were
used as a control because they lack the adaptive arm of the
immune response, but are otherwise genetically identical to NOD,
allowing us to trace non-immune developmental processes in islets.
Two additional controls strains were used in this study to increase
the robustness of the analysis. The B6.NOD-H2g7 strain (B6.g7)
was chosen because it expresses the MHC-II protein I-Ag7 on
a C57BL/6 background. This strain does not develop diabetes.
We also used C57BL/6 mice as our most normal control strain.
Examination of the entire data set by Spearman’s rank
correlation showed a low variance amongst all data (Fig. S1A,
Spearman’s Rank ,0.089). By Spearman’s Rank, the data was
grouped mainly by the age of the mice. Similarity in variance
amongst the 2 and 6 wk old mice was independent of background
strain. The outliers in the data set were the 8–18 wk NOD mice
and the newly diabetics. In particular the 8 wk NOD mice were
most distant in variance from the rest of the data.
The Earliest Transcriptional Difference between NOD and
Control Mice, Including NOD.Rag12/2 Mice, was an
Interferon Signature
First, we looked at transcriptional difference between the two
genetically closest diabetic and non-diabetic strains (NOD and
NOD.Rag12/2). Since the main difference between these mice is
the presence of an adaptive immune response, we reasoned that
only immune system dependent changes would be found between
the two strains. We performed pair-wise comparisons of NOD and
NOD.Rag12/2 mice at 2 and 6 wks of age (Fig. 2A–F). At 2 wks of
age, there were 19 detectable differences between NOD and
NOD.Rag12/2 mice. Overall, there were very few differences
between 2 wk old NOD and NOD.Rag12/2 mice and no obvious
differences related to immune responses.
By 6 wks of age, we found 24 significant differences between
NOD and NOD.Rag12/2 (Fig. 2B–C). We found 14 genes more
highly expressed in NOD than NOD.Rag12/2 and 10 genes more
highly expressed in NOD.Rag12/2 than NOD. The transcripts
with higher expression in NOD were all IFN-inducible transcripts.
For our study, interferon-inducible genes were defined based on
the microarray analysis of Liu, et al. [19]. The interferon signature
increased in magnitude over the time course of NOD de-
velopment, and was not found in any of the other control non-
diabetic mice (Fig. 2C). (Many of the expression differences
between 6 wk old NOD and NOD.Rag12/2 mice were detectable
as early as 4 wks of age in NOD; see below for details.).
Next we interrogated changes that took place between 2 and
6 wk old mice in NOD or NOD.Rag12/2 mice. There were
,1000 significant changes between 2 wk and 6 wk old NOD and
between 2 wk and 6 wk old NOD.Rag12/2 mice (Fig. 2D–E).
Gene ontology and promoter scanning of the genes commonly
upregulated in both strains showed that they were involved in cell
division, cell cycle, and cellular adhesion. They also included
promoter binding sites for early developmental regulators, such as
SP1 (Fig. 2F). This indicated that the islet of Langerhans was still
actively dividing and developing from 2 to 6 wks of age regardless
of diabetes susceptibility.
In addition to upregulated genes, a number of transcripts were
downregulated between 2 and 6 wk NOD and NOD.Rag12/2
mice. The level of downregulated transcripts was comparable in all
strains, including B6.g7 and C57BL/6 mice. Analysis of variance
of the 6 wk downregulated genes by Spearman’s rank grouped
most of the 6 wk samples together, and the main outlier was the
8 wk NOD (Fig. S1B). Analysis of the downregulated signature
showed an enrichment of transcriptional regulatory genes (Fig.
S1C). Euclidean distance and Pearson’s Correlation analysis did
not provide a discernible trend in the downregulation of
transcripts through the time course of NOD mice development
(Fig. S1D, Data not shown).
In summary, pairwise analysis of 2 and 6 wk old NOD and
NOD.Rag12/2 mice showed mostly a regulation of cell growth
and development, and an inflammatory response unique to NOD.
A surprising finding was the fact that as early as 6 wks of age an
interferon-dependent gene signature was already found in NOD
mice, but not in any of the 6 wk old controls. Many of the 6 wk
inflammatory changes were evident in NOD mice as young as
4 wks, as will be detailed below.
Principal Component Analysis Revealed that the Major
Source of Transcriptional Variance between NOD and
Control Mice was Immunological in Nature
Principal component analysis (PCA) was used to evaluate the
transcriptional changes responsible for the highest variance of the
dataset [20]. PCA discriminated our samples by both strain and
age (Fig. 2G). We extracted the top 1% of transcripts responsible
for the overall PCA variance and this yielded transcripts that
correlated with a progression in the age of NOD mice (Fig. S1C).
Two salient features were identified by PCA and noted in Fig. 2H.
The first was a group of genes selectively upregulated as early as
4 wks of age in NOD mice. These were immune response genes,
including the interferon inducible genes mentioned in Fig. 2C. A
second group of genes was selectively upregulated on or after
8 wks in NOD mice. This group was enriched for immune
response and a variety of leukocyte specific and interferon-
inducible genes. Key leukocyte cell surface markers, including Cd2,
Cd3e/d/g, Cd4, Cd8a, Cd19, Cd22, T cell receptor, B cell receptor
and immunologically important signaling components such as Lck,
Lat, and Cd79b, were identified by PCA. Analysis by Gene
Ontology and promoter scanning showed that genes identified by
PCA were significantly enriched for immune response and antigen
processing and presentation signatures and IRF1 was the most
significant transcriptional regulator (Fig. 2I).
Refined Staging of NOD-specific Transcriptional Changes
in the Islets of Langerhans
In order to better identify transcriptional changes positively
correlated with a progression toward diabetes, we performed k-
means clustering using uncentered Pearson’s correlation. Our goal
was to focus on genes with a positive Pearson’s correlation
throughout diabetogenesis and with lower relative expression in all
our controls.
The dataset was clustered as shown in Fig. S2A. Several clusters
contained groupings of genes with a positive correlation of
Transcriptome Analysis of Islets of Langerhans
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expression throughout diabetogenesis. The clusters that were
chosen were highlighted in red and demonstrated an increase in
gene expression intensity throughout diabetogenesis, but had
relatively lower expression levels in all controls. Using this analysis
Figure 2. Pairwise and principal component analysis of microarray data. (A–B) Scatter-plots of the normalized probe intensity of all
annotated microarray signals are shown. Each dot represents the mean of 6 independent biological replicates. Numbers in the box represent the
number of features that were at least 2-fold different at a 99% confidence interval by moderated t test with Benjamini-Hochberg false discovery rate
analysis. Data are plotted at a log2 scale. Panel (A) compares NOD.Rag
2/2 mice versus NOD mice at 2 wks of age and panel (B) compares them at
6 wks of age. (C) Hierarchically clustered heat map (Euclidean row distance) of the 24 differentially expressed transcripts identified in (B). (D–E)
Scatter-plots as in (A–B) except the comparison is between 2 and 6 wk old NOD or 2 and 6 wk NOD.Rag2/2. (F) GO terms and transcription factor
binding analysis of the differences identified in (D–E). The two graphs on the left, labeled ‘Shared’ show signatures common to both NOD and
NOD.Rag2/2. The signatures on the right, labeled ‘NOD only’, show changes specific to the NOD strain. (G) Principal component analysis of
microarray samples. Each of 57 microarrays is summarized as a point and drop-line. Samples are color coded as indicated by the title of each group.
(H) Hierarchical clustered heat map (Euclidean distance) of the top 1% most variant genes identified by principal component. (i) GO and transcription
binding analysis of the top 1% most variant genes identified by principal component analysis.
doi:10.1371/journal.pone.0059701.g002
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we identified 888 genes that were selected for further analysis.
Pearson’s correlation excluded most of the developmental changes
mentioned previously, but included immune-related genes changes
missed by pair-wise analysis and PCA (Fig. S2C). Also, Spearman’s
rank correlation analysis of the genes identified by Pearson’s
showed a delineation of NOD mice at different ages (Fig. S2B).
The genes identified by Pearson’s were superimposed with pair-
wise comparisons performed between 2 wk old NOD and the age
in question. This allowed us to establish genes that were
significantly upregulated in NOD mice of different ages. For
example, there were 634 significantly upregulated genes between
2 wk and 4 wk old NOD mice (2-fold, 99% C.I.) and the
intersection of these changes with Pearson’s Correlation yielded 81
significant changes at 4 wks (Fig. 3A, Table S1). These 81 genes
included all 14 of the upregulated genes identified in Fig. 1A–C.
The remaining genes were upregulated $2-fold in NOD and to
a lesser extent in the controls (see below).
For subsequent time points, we combined the intersection of
Pearson’s Correlation with pairwise statistics at a given age (6, 8,
12, 18, and newly diabetic), but excluded changes already
significant at a previous time. Fig. 3B–C shows an example of
this for 12 wk and newly diabetic changes. In the case of the 12 wk
sample, 70 new significant changes were detected and in newly
diabetic mice 205 new significant changes were detected. We used
the changes identified this way to determine the presence of
immune signatures during diabetogenesis.
Detailed Analysis of Immune Signatures during T1D
To dissect the transcriptional profiles of T1D progression, we
combined transcription factor binding analysis (p-scan), gene
ontology, and the modules and regulators dataset of the
Immunogenetics Consortium (Immgen) [15,21–24]. The idea
was to add power to our approach by using groups of genes instead
of analyzing any single individual transcript. Based on this
approach, we parsed out the results previously shown in Fig. 3
and Table S1 as shown in Fig. 4.
At 4–6 wks of age NOD mice displayed an interferon
transcriptional signature, determined by the enrichment of IRF1
and IRF2 binding sites on the promoters of upregulated genes.
Cellular response to IFN-b and IFN-c were the two most enriched
GO Terms. There was also a significant but weak developmental
signature (RUNX1 and Myf; Fig. 4).
Using Immgen’s modules and regulators we found 12 genes that
were myeloid specific and that we termed as an ‘‘early myeloid’’
signature (Fig. 4B). Most of the early myeloid signature was found
in all strains, but increased over time in NOD mice. The early
myeloid genes were not specific for any identifiable leukocyte, but
many were linked to antigen processing and presentation (H2-Ab1,
H2-Eb1, H2-Aa, and Cd74). This signature is compatible with an
intra-islet myeloid cell previously described by our group and
others [25–27].
By 8 wks of age, there was a significant upregulation in genes
regulated by SPI1 (myeloid regulator) and SPIB (B lymphocyte
regulator). At this time, all major leukocyte subsets implicated in
the development of diabetes were represented transcriptionally.
Gene ontology showed enrichment of chemotaxis and T cell
activation signatures. Definitive T cell specific genes including Cd2,
Cd3d, Cd3g and also a signature of T cell activation as defined by
Ctla4, Slamf1, Slamf6, Slamf7, Slfn1 (Shlafen1), and Cxcr5 was
defined. B cell specific genes, including the immunoglobulin and
Ig-associated genes Igk, Igl, and Cd79b were also detected (Fig. 4,
Table S1). Natural killer cells were identified by the induction of
genes belonging to the NK gene cluster (Klrc1, Klrd1, and Klra17;
Table S1) [28]. In 8 wk old NOD, we found 38 new myeloid
transcripts, which we termed the ‘‘late myeloid’’ and included
markers enriched on monocytes, macrophages, and dendritic cells,
such as 5 members of the c-type lectin family Clec4a1, Clec4a2,
Clec4a3, Clec4n, Clec12a (Fig. 4B and Table S1).
At 12 wks of age a second wave of IRF1/IRF2 response was
detected. This corresponded to a GO profile that included antigen
processing and presentation and positive regulation of T cell
mediated cytotoxicity (Fig. 4A). At 18 wks there was further
amplification of the response, increased IFNc and IL-2 dependent
gene expression, and a continued myeloid signature as evidenced
by SPI1 regulated transcripts. Finally, newly diabetic mice showed
an enrichment of NF-kB inducible transcripts (Fig. 4A).
Examination of transcriptional changes by Pearson’s correlation
and ANOVA demonstrated that the inflammatory gene upregula-
tion during diabetogenesis occurred in 5 major patterns. Co-
ordinated upregulation of various transcriptional groups was found
at 4, 8, and 18 wks as well as in newly diabetic mice. There was
also a steady upregulation profile (Fig. S3).
Chemokines are considered the drivers of specific immune cell
entry into tissues. We found 4 chemokine genes were upregulated
by 4 to 6 wks: Ccl3, Ccl5, Ccl19 and Cxcl9 (Fig. 4B). Of these, Ccl5
and Cxcl9 were higher in NOD than in controls. None of the
chemokine receptors for Ccl5 or Cxcl9 were detectable in 4 or
6 wks old NOD. The only chemokine receptor to be found
significantly upregulated in NOD at 4 and 6 wks was Ccr2,
a receptor enriched in blood monocytes but also expressed on
some populations of dendritic cells. Therefore, at 4 and 6 wks
there was not a detectable chemokine-chemokine receptor pairing
that could be responsible for the entry of any specific leukocyte
subset. However, by 8 wks of age there was NOD-specific
upregulation of 11 chemokines and 7 chemokine receptors
(Fig. 4B). The chemokines included ligands for recruitment of
naı¨ve (Ccl19), memory (Cxcl9/10), and activated ab T cells (Cxcl9/
10). We also detected at least one ligand for the recruitment of cd
T cells (Ccl22), regulatory T cells (Ccl22), B cells (Cxcl13), NK cells
(Ccl4, Cxcl11), conventional and plasmacytoid DC (Cxcl11, Ccl4),
blood monocytes (Ccl2), macrophages (Ccl2, Ccl5), and neutrophils
(Xcl1). Chemokine receptors for all major leukocyte populations
were also found, with the exception of granulocytes. The pattern
of chemokine and chemokine receptors remained mostly un-
changed after 8 wks of age, except for the increase of Cxcr4 and
Cxcr6 at 12–18 wks of age. The data show that at the chemokine/
chemokine receptor expression level the ability to recruit all major
leukocyte subsets involved in the progression of diabetes was in
place by 8 wks of age.
Our approach detected 5 significantly upregulated adhesion
molecules: Glycam1, Vcam1, Icam1, L1cam, and Amica1. All adhesion
factors were significantly upregulated only in the NOD mice.
Vcam, Icam1 and L1cam were upregulated by 4 to 6 wks of age,
Amica1 was upregulated by 8 wks of age and Glycam1 was
upregulated by 12 wks of age. Glycam1 was the most upregulated
adhesion factor throughout diabetogenesis. Integrins that were
significantly upregulated after 12 wks of age included Itgb2
(CD18), Itgae (CD103), Itgax (CD11c), Itga4 (CD49d), and Itgb7.
Overall the adhesion factor and integrin signature points to an
enrichment of myeloid cell types. A concomitant upregulation of
expression of the pan-leukocyte marker Prptc (CD45) and modest
changes in islet-specific genes were also detected (Fig. S4).
Examination of Interferon and Interferon-inducible Gene
Expression by Quantitative RT-PCR
We validated 8 candidates genes that were significantly
upregulated between 4 and 8 wks in our microarray data set
using qRT-PCR: Cxcl9, Stat1, Gbp2, Iigp1, Rtp4, Gpr18, Oasl2 and
Transcriptome Analysis of Islets of Langerhans
PLOS ONE | www.plosone.org 5 March 2013 | Volume 8 | Issue 3 | e59701
Transcriptome Analysis of Islets of Langerhans
PLOS ONE | www.plosone.org 6 March 2013 | Volume 8 | Issue 3 | e59701
Tgtp1. Fig. 5 shows the results of the RT-PCR data (Panel A) and
microarray data (Panel B) for the 8 validated targets. By RT-PCR
there was significant upregulation of all 8 transcripts in 4 to 6 wk
old NOD mice when compared to 2 wks. Cxcl9 and Gbp2 were
significantly upregulated from 2 to 4 wks in NOD and were
significantly different from all control strains at 6 wks of age
(Fig. 5). As with our microarray results, certain genes, like Rtp4
were upregulated in NOD from 2 to 4 wks, but had comparable
expression levels with controls at 6 wks of age. Both of these
observations were in agreement with the microarray results and
support the idea that there is an entry of leukocytes that is
universal to all strains of mice and a second signature that is
interferon-inducible enriched and specific to NOD (Fig. 5B, Table
S1).
We wanted to determine which interferons were transcribed in
the islets of Langerhans. We reliably found a ‘‘tonic’’ transcript for
Ifna in the islets, pancreatic lymph nodes and spleens of all strains
of mice and at all times examined (Fig. 5C which only shows data
from islets). There was a small level of upregulation from 2 to
4 wks in NOD mice, but expression levels were 10 to 100-fold
higher than in the three control strains. Ifnb transcripts also were
reliably detectable in the islets of all mice, and sporadically in the
spleens and lymph nodes of NOD (Fig. 5C, data not shown). The
levels of Ifnb expression did not go above the tonic expression level
until 6 wk of age. At this time there were .10 fold more
detectable transcripts in NOD than in C57BL/6, B6.g7 or
NOD.Rag12/2 mice islets. To note, pancreatic lymph nodes of
NOD mice contain a detectable expression of type I interferon in
plasmacytoid DC, as early as 3 wks of age [14].
In contrast to type I interferon, we did not detect tonic
expression of Ifng in the spleens or lymph nodes of NOD or the
control mice (Fig. 5C, and data not shown). Reliable expression of
Ifng was only detected at 8 wks with maximal expression at 12 wks
in NOD. This coincided with the first detectable Ifng by
microarray. Based on this data, we conclude that type I interferon
was expressed before Ifng during diabetogenesis. The timing of
significant upregulation of Ifna and Ifnb appears to be simulta-
neous.
Integration with Protein-protein Interaction Networks
Shows Immune Subnetworks Dominating Across
Diabetes Development
We related the islet gene expression data in the context of
established protein-protein interaction networks. First, we dissect-
ed the temporal changes in gene expression of our dataset by
computing pairwise p values for all permutations of samples. This
was done in order to identify the genes that became involved in
diabetogenesis at a given age. For example, at 8 wks of age, we
looked for differential expression from 2 to 6 wk NOD versus 8 to
newly diabetic NOD. By this analysis, only genes that became
significantly upregulated at 8 wks, but were not significant at all
previous times were analyzed.
Subnetworks of genes upregulated at 6 wks contained a cluster
of AP-1 related immune genes specific for myeloid lineage (Fos,
Junb, Jun, Fosb, etc). The 8 wk subnetwork was strongly enriched
for ‘‘Genes involved in Signaling in Immune system’’ (Reactome,
hypergeometric p value ,10212) and ‘‘T Cytotoxic Cell Surface
Molecules’’ (Biocarta, hypergeometric p value ,10210). The 18-
wks subnetwork showed strong enrichment in members of both T-
cell and B-cell receptor pathway (hypergeometric p values of 1026
and 1025, respectively; Fig. 6).
We expanded these observations by cross-referencing time point
specific genes with profiles available in the Immgen database [15].
Since Immgen-derived transcriptional modules available online
are defined based on the human immune cell types, we used the
enrichment score strategy introduced in Benita, et. al. to compute
the representation of murine immune cell types within transcrip-
tional signatures of infiltration [29]. Consistently, the 4 wk NOD
signature did not show statistically significant enrichment in
immune cell types, while the 6 wk NOD signature showed non-cell
type specific increase of immune cell types illustrated by
hematopoietic progenitor transcriptional signatures. Strikingly,
the 8, 12, 18 wk, and newly diabetic NOD mice showed a specific
sequence of immune infiltration. In 8 wk NOD mice transcripts
infiltration by CD8 and cdT cells was enriched (Fig. 6 and Fig.
S5). This was followed by a myeloid cell re-infiltration at 12 wks,
and B cell infiltration at 18 wks. Finally, newly diabetic NOD mice
had strong cytotoxic helper T cell signature. This was consistent
with both direct observation of islet-infiltrating cell-types and
strongest interacting subnetworks identified in the data (Fig. 6),
and showed that expression profiles were informative for dissecting
heterogeneous cell populations.
Discussion
Several important milestones in the development of diabetes
were derived from a chronological transcriptional analysis that was
complemented by cytological analysis of the islets. Examination of
individual genes can introduce observational bias. However the
addition of Immgen, promoter scanning, ontology analysis, and
modeling added an important layer of additional information.
This approach allowed us to parse complex lists of genes and cells
into an improved definition of the steps leading to T1D and to
identify different stages in its progression. Previous microarray
analyses of T1D used either accelerated methods for inducing
disease or interrogated a subset of the pancreatic infiltrate[9,11–
13,30]. Thus, the events leading to diabetes were temporally
compressed or only a subset of the response was analyzed. Despite
these limitations, important candidate markers for diabetes were
identified, including genes that distinguish progressive versus non-
progressive disease [30]. We have greatly expanded on our
available datasets and present the first complete analysis of the
entire natural diabetic program.
The time at which NOD mice become diabetic is heterogeneous
and gender dependent. Despite the stochastic endpoint, the
progression of the program that culminates in overt disease was
Figure 3. Identification of significant gene changes in different aged NOD mice. Examination of transcriptional changes that took place
between 2 wks and either (A) 4 wks, (B) 12 wks, or (C) newly diabetic NOD mice. The red portion of each Venn diagram shows the genes identified
by Pearson’s correlation as following a positive correlation throughout diabetogenesis. The green portion of each Venn diagram shows statistically
significant changes from 2 wks to the given wk as determined by 2-fold upregulation and 99% confidence interval by moderated t test with
Benjamini-Hochberg false discovery rate analysis. The blue portion of the Venn diagrams is the intersection of all the pairwise statistically significant
differences from 2 wks to the indicated ages. Hierarchically clustered heat maps show the Euclidean distance of genes identified by the yellow
intersection in the Venn diagrams. Those were the genes that showed both a positive correlation by Pearson’s correlation and a pairwise fold and
statistical change at the indicated time. Gene names in red are type I interferon-inducible and those in green are inducible by both type I and type II
interferons.
doi:10.1371/journal.pone.0059701.g003
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relatively conserved and several important milestones were
identified. During the first 4 wks of life, myeloid cells populated
the islets, independently of diabetes susceptibility. The first major
transcriptional event that differentiated the NOD from control
mice was the expression of type I interferon, reliably detected by
the 4th wk of age. The expression of type I interferon was
correlated with a discrete appearance of CD4+ T cells inside the
islets. The second milestone was the coordinated infiltration of
islets by all major inflammatory cells by the 8th wk of life. This
event was synchronous with markers of T cell activation and
a dramatic change in islet-specific gene expression. Between the 12
and 18th wk there was further diversity in the expression of genes
linked to cytotoxicity, many of which were NF-kB inducible.
Despite a prolonged inflammatory infiltrate starting at 8 wks, mice
did not become diabetic until after 20 wks of age, indicating
a partial level of control for a period of time.
The earliest expression of the autoimmune state was the type I
interferon signature, its importance cannot be underestimated. It
was not unexpected to find a level of constitutive type I interferon
in the islets as well as in other tissues [31,32]. The key event
however was the marked upregulation at 4 to 6 wks of age. Future
experiments will need to address the causes and effects of the type I
IFN expression. For one, we need to explain the relationship
between type I IFN production and the finding of early infiltrating
T cells, the specificity of which needs to be examined. Because of
their striking contact with islet APC these T cells should be
recognizing b-cell antigens. Surprisingly, genes linked to T cell
activation were not detectable until 8 to 12 wks of age in NOD.
The type I interferon induced Cxcl9 that develops early in NOD
has the ability to recruit both pathogenic and regulatory T cells
that bear the Cxcr3, the receptor for Cxcl9. It is possible that the
naı¨ve T cell is incapable of being diabetogenic until it has been
converted to an effector/memory phenotype at distal sites, such as
the pancreatic lymph node, a site which has been shown important
in diabetes development [33,34]. T cells that initiate the diabetic
process may become regulated at 8 wks, but the entry of effector
memory cells that are conditioned in the lymph node may cause
the process to move forward starting at ,12 wks.
Concerning other stimuli, we have no evidence for viral
infections in our colony, an issue that has been examined with
care. But pointedly, gnotobiotic NOD mice still developed
diabetes, although the microbiome did influence its development
[35]. Nucleic acids have been defined as the most potent agonists
of type I interferon production [36]. DNA released by apoptotic b-
cells could activate nucleic acid sensor pathways for the induction
of type I interferon. Inflammatory nucleic acids may result from
the developmental changes that were detected during the first
4 wks. Importantly, an early apoptotic event has been discussed as
a possible inductive phase of diabetes [37]. Alternatively, multiple
signals may be required for the type I interferon burst which
coincides with the initiation of immune infiltration. This hypoth-
esis has been recently postulated for the induction of lupus, a type I
interferon mediated autoimmunity [38]. Careful evaluation of
different nucleic acid sensor pathways in NOD is lacking and is an
important future direction.
Finally, we note some of the reports in the literature that
reinforce the importance of a type I interferon response. Analysis
of RNA isolated from whole pancreatic lymph nodes demonstrat-
ed an upregulation of type I IFN in NOD mice from 2 to 3 wks
[14]. However, it is not clear if this upregulation is unique to NOD
mice. Treatment of mice with type I interferon neutralizing
antibodies delayed disease incidence. Higher level of Ifna
expression was found in the pancreases of human T1D patients
with end-stage disease when compared to normal controls [39].
Diabetes prone BB rats and mice treated with streptozotocin had
expression of type I interferon in their pancreatic islets [40]. There
are reports of patients treated with type I interferon for chronic
viral infections that then developed diabetes [41]. In the case of
mice, enforced expression of type I interferon in islets caused
autoimmune diabetes [42,43]. The transcription factor Irf7, a key
regulator of type I interferon upregulation, has been linked to T1D
by genome-wide association studies [44]. There is an abundance
of data demonstrating the importance of type I interferon in other
autoimmune diseases [45].
The microarrays at 8 wks of age not only marked the detection
of all major leukocyte subsets, but also showed changes in islet
specific gene expression. We detected downregulation of tran-
scription factors essential for islet development and function.
Additionally, by variance analysis these arrays were more distant
from all other arrays regardless of whether the genes were
unfiltered, selected by PCA, or by Pearson’s correlation. We
believe, as do others, that this is due to a control mechanism
established in the islets that must be overcome before disease can
progress [30]. Multiple genes involved in T cell regulation such as
Ctla4, Cd52, Havcr2, Cd244, Btla, Cd200, and Cd274 were
upregulated at 8 wks of age, indicating the potential presence of
a control mechanism. By microscopy we were able to detect
FoxP3+ regulatory T cells in the islets of NOD mice at 8 wks of
age. The demonstration of the importance of regulation in control
of disease was shown in NOD mice deficient in functional FoxP3,
which developed diabetes at a faster rate than wild-type control
mice [46,47]. The concept of a regulatory balance at ,8 wks has
been shown by altering Treg:Teff levels using IL-2 treatment [48].
Removal of Foxp3+ Tregs in a BDC2.5 TCR transgenic model of
T1D revealed an increase in Ifng signatures, which was associated
with progression of disease [49].
In addition to T cell/Treg specific signatures, examination of
NOD mice showed that macrophage gene expression profiles, in
particular the expression of Vsig4 (CRig), was predictive of pro-
gression to disease [30]. The presence of a CRig+ macrophage at
10 wks was indicative of a resistance phenotype, and modulation of
this population by CRig-Fc treatment protected NOD mice from
becoming diabetic. It will be interesting to determine if the
inflammatory changes detected between 8 and 12 wks are related
to the loss of the protective macrophage signature and whether this is
the final trigger that leads to overt diabetes.
Concerning Ifng, we found expression at 8 wks in NOD mice,
but the maximal signal was not detected until 12 wks of age.
Signaling induced by this cytokine results in different biological
effects depending on the cellular targets and their activation state.
In NOD protective as well as proinflammatory responses have
been reported [50,51]. Whether Ifng expression in early versus late
diabetogenesis results in different biological responses remains an
issue for future consideration.
Figure 4. Analysis of inflammatory genes changes throughout diabetogenesis. Differentially expressed genes identified in Figure 3 and
Supplemental Table 1 were interrogated for transcriptional regulation signatures and gene ontology (A) or for their immunological role (B). (A) Cell
enrichment, transcription factor binding, and gene ontology analysis were performed. Numbers in parentheses indicate the number of cell type
specific genes identified as statistically significantly changed at the given age. (B) Hierarchically clustered heat maps of cell type specific gene
changes throughout diabetes. Values were adjusted to a per row color scale so all changes were relative to 2 wk NOD mice.
doi:10.1371/journal.pone.0059701.g004
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In sum, discrete transcriptional profiles were identified in the
diabetic autoimmunity of the NOD mouse, a chronic progressive
and multifactorial disease. This information may set the base to
analysis and identification of causative events but also to better
define gene markers that can be used to identify the stages of the
human disease.
Figure 5. Quantitative RT-PCR validation of microarray data. (A) Quantitative RT-PCR was performed using SYBR green detection for the
indicated genes. Bars show the mean (log2) +/2 S.E.M. of at least three independent experimental replicates from 3–6 biological replicates per group.
All data is represented relative to the expression of actin (DCt). In order to facilitate visualization on a log2 scale, values were transformed as indicated
on the y-axis label. (B) Microarray results for the same genes interrogated in (A). (C) Taqman qPCR quantification of pan-IFNa, Ifnb1, or Ifng
throughout diabetogenesis. Bars represent the mean of the normalized probe intensity +/2 S.E.M. of 3–6 biological replicates per group. Asterisks
indicate statistical significance (P,0.05) from 2 wk NOD sample by one-tailed Mann-Whitney test.
doi:10.1371/journal.pone.0059701.g005
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Materials and Methods
Mice
NOD (NOD/ShiLtJ), NOD.Rag12/2 (NOD.129S7(B6)-
Rag1tm1Mom/J) and B6.g7 (B6.NOD-H2g7) mouse strains were
bred at Washington University School of Medicine. C57BL/6
mice were obtained from The Jackson Laboratory (Bar Harbor,
ME). All of the mice used in this study were female mice. We
identified the diabetic mice following two consecutive daily blood
glucose readings $250 mg/dl. In our NOD colony, the incidence
Figure 6. Data modeling of transcriptional networks. The most significant interaction networks were calculated at (A) 6 wks (FDR 0.00006), (B)
8 wks (FDR= 0.0000001) and (C) 18 wks of age (FDR=0.00012). Interaction significance was based on the p values calculated for each age group.
Notably, at 6-wk, strong developmental signature persists along with AP-1 module, generally attributed to myeloid cells. At 8-wks, strongest
interacting subnetwork is T-cell specific, while 18-wk additional B-cell and cytoskeleton specific modules appear.
doi:10.1371/journal.pone.0059701.g006
Transcriptome Analysis of Islets of Langerhans
PLOS ONE | www.plosone.org 11 March 2013 | Volume 8 | Issue 3 | e59701
of diabetes in female mice is ,90% with incidence ranging
between ,20–30 wks of age. All of the 18 wk old mice had
normal blood glucose for at least two days before being sampled.
All mouse experiments were approved by the Division of
Comparative Medicine of Washington University School of
Medicine (Association for Assessment & Accreditation of Labora-
tory Animal Care (AAALAC) accreditation number A3381-01).
Experiments were performed under institutional guidelines and all
efforts were made to minimize suffering. The institutional
approval number for these studies was protocol number
20110150.
Islet Isolation and Handling for Immunofluorescence
Islets were isolated with some modifications of the original
protocol [52–54]. Briefly, pancreata were isolated and treated
with collagenase, followed by several steps of centrifugation and
washing, and finally, islets were hand-picked. Immunofluores-
cence analysis was performed as previously described [25].
Resident leukocytes, infiltrating leukocytes, adhesion molecules
(ICAM-1 and VCAM-1), blood vessels and IgG antibody
deposition in the islets were detected with the following
monoclonal antibodies: anti-CD11c Alexa FluorH 488 (clone
N418), anti-CD19 phycoerythrin (PE) (clone 6D5), and anti-
CD4 PE (clone RM4–5) from BioLegend, Inc., San Diego, CA,
anti-CD8a PE (clone 53-6.7; BD Biosciences, San Jose, CA),
anti-CD31 Alexa FluorH 647 (clone 2B8, kindly provided by Dr.
Steven Bogen, Boston University School of Medicine, Boston,
MA), and anti-mouse IgG Alexa FluorH 488 (Invitrogen,
Carlsbad, CA). Biotinylated antibodies against ICAM-1
(CD54, clone Yn1/1.7.4) and VCAM-1 (CD106, clone 429)
were obtained from eBioscience. Streptavidin Alexa FluorH 488
or 555 (Invitrogen) was used as the secondary reagent.
Percentages of infiltrating leukocytes, adhesion molecules
expression and IgG deposition were evaluated from 50 to 100
islets per mouse with groups of 4 to 6 mice per time point.
Flow Cytometry
Isolated islets were dispersed in a water bath using Cell
Dissociation Solution Non-enzymatic (Sigma-Aldrich) for 15
minutes at 37uC. Islets were then pipetted several times and
then passed through a pre-wet 40 mm cell strainer and washed
twice in Dulbecco’s minimal essential medium with 10% fetal
calf serum. Dispersed islet cells were stained with labeled
antibodies against CD45 FITC (clone 30-F11), CD4 PE (clone
RM4-5), CD19 PE (clone 6D5) and CD11c APC (clone N418)
from BioLegend, Inc. CD8b APC (clone eBioH35-17.2) and
Foxp3 (clone FJK-16s) were obtained from eBioscience. Foxp3
staining was performed following the manufacture’s protocol.
Flow cytometry analysis was performed on a FACSCalibur (BD
Biosciences) and data was analyzed using FlowJo software (Tree
Star).
RNA Isolation
For islets of Langerhans (,100), Total RNA was isolated
using the Ambion RNAqueous-Micro Kit (Life Technologies,
Carlsbad, CA, USA) following the manufacturer’s instructions.
For spleen and lymph nodes, RNA was isolated using Trizol
(Life Technologies) following the total tissue RNA protocol.
RNA was quantified by OD260 using Nanodrop (Thermo
Fisher Scientific, Wilmington, DE, USA). For microarray
analysis, RNA integrity and quantification was further validated
using a Bioanalyzer (Agilent Technologies, Santa Clara, CA,
USA).
Microarray Analysis
RNA (50 ng) was amplified using NuGEN PicoSL WTA System
or NuGEN PicoPure (NuGEN, San Carlos, CA, USA) following
the manufacturer’s instructions. Amplified RNA (100 ng) was
labeled using Affymetrix GeneChip Whole Transcript Sense
Target Labeling Assay following the manufacturer’s instructions
(Affymetrix, Santa Clara, CA, USA). Labeled RNA was hybrid-
ized to Mouse Gene 1.0 ST microarrays using a GeneChip
Fluidics Station 450 (Affymetrix). Microarrays were scanned using
a GeneChip Scanner 3000 7G (Affymetrix). All GeneChip
processing steps were performed by the Laboratory for Clinical
Genomics at Washington University School of Medicine.
Initial quality control analysis of scanned microarray files was
performed using Expression Console software (Affymetrix). Array
data (.cel files) was imported into Arraystar 5 software (DNAstar,
Madison, WI, USA) and then normalized using the robust multi-
array analysis method with quantile normalization [55]. Normal-
ized data was exported as normalized linear signal intensity and
then batch effect correction was performed using the Combat
module of GenePattern [16,56]. The batches were as follows: 1)
NOD.Rag2/22 wk and 6 wk, NOD 2 wk, B6.g7 6 wk, C57BL/6J
6 wk; 2) NOD 4 wk, 6 wk (arrays 4–6), and newly diabetic, 3)
NOD 6 wk (arrays 1–3), 8 wk, 12 wk, and 18 wk. All raw data
files (CEL) are publicly available in the Gene Expression Omnibus
as accession number GSE41203.
Normalized and batch corrected data was used for all sub-
sequent analyses.
Spearman’s Rank Correlation was calculated using GENE-E
Software (Broad Institute http://www.broadinstitute.org/cancer/
software/GENE-E/). Principal component analysis was per-
formed using Population PCA software (CBDM Laboratory,
Harvard University, http://cbdm.hms.harvard.edu/
LabMembersPges/SD.html). For all pairwise tests contained
herein, we set our threshold at two-fold change with a 99%
confidence interval by moderated t test with Benjamini-Hochberg
False Discovery Rate analysis [57]. Hierarchical clustering analysis
and heat map plot generation was performed using Arraystar 5.
Gene Ontology analysis was performed using GeneCoDis 3.0
(http://genecodis.cnb.csic.es/analysis/; [22]). Promoter scanning
analysis was performed using Pscan (http://159.149.109.9/pscan/
; [23]) with the 2950+50 settings and Jaspar mouse database.
Batch name conversion was performed using the MGI Batch
Query (http://www.informatics.jax.org/batch/?page = batchQF).
For selecting genes specific to particular cell types we used the
Immgen Modules and Regulators. The following modules were
used: myeloid cells (macrophage, DC, granulocytes): coarse
modules 25, 26, 48, 58, and 74, T cells: coarse module 146, B
cells: coarse module 33, and NK cells: coarse module 19. Venn
diagrams were generated using Arraystar 5. Pearson’s Correlation
analysis was performed using Arraystar 5. Bar graphs and
statistical analysis was performed using Graphpad Prism 5.0
(Graphpad Software, Inc., La Jolla, CA, USA). Hypergeometric p
values were calculated using the dhyper function of R. All figures
were laid out using Adobe Illustrator CS5.
Real Time PCR
Complementary DNA was made from total RNA using
TaqMan Reverse Transcription Reagents (Life Technologies)
following the random hexamer protocol. Primers for quantitative
RT-PCR for Cxcl9, Stat1, Gbp2, Iigp1, Rtp4, Gpr18, Oasl2, and Tgtp1
were designed using Primer Bank (http://pga.mgh. harvard.edu/
primerbank/; [58]. TaqMan primers and probes for amplifying
and detecting Ifng and Ifnb were obtained from Life Technologies.
Primers and probe for detecting all the Ifna transcripts were made
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based on previous work [59]. SYBR green PCR was performed
using Fast SYBR Green PCR Master Mix (Life Technologies)
following the manufacturer’s instructions. TaqMan PCR was
performed using TaqMan Fast Universal PCR Master Mix (Life
Technologies). All qPCRs were performed on a StepOnePlus
Real-Time PCR system running StepOne Software. Quality
control and relative expression quantification for qPCR was
performed by the StepOne software.
Network Analysis
The R package Bionet was used to identify subnetworks
significantly enriched in genes differentially expressed at any
given time point of diabetes development [60]. For each time point
we scanned a range of false discovery rates and chose a subnetwork
of 20–30 genes in size (p,0.05 by FDR).
Cell type enrichment scores were pre-computed enrichment
scores for all genes based on mouse Immgen data. This included
data for 193 immune cell types/subtypes and then applied
a hypergeometric test to look for overrepresented set of genes.
For each time point we chose a corresponding test set that
consisted of the top 100 differentially expressed genes (all with p
values ,0.05). Equal numbers of genes were chosen for each time-
point such that we could use a union of all test sets as background
in hypergeometric test (Table S2).
Supporting Information
Figure S1 Summarization of microarrays data throughout
analysis. (A) Summarization of all normalized and curated genes
in our dataset. (B) Summarization and analysis of all genes
downregulated between 2 and 6 wks in NOD and NOD.Rag2/2
mice. The Venn diagram shows all genes downregulated at least 2
fold at 99% C.I. following F.D.R. analysis. Genes downregulated
in NOD are in red, genes downregulated in NOD.Rag2/2 are in
green. Shared genes are in yellow. The shared group of genes were
analyzed by transcription factor biding site enrichment (Pscan) or
Gene Ontology enrichment (GeneCoDis). Bar graphs show the
corrected p value for each type of analysis. The heat map shows
the hierarchically clustered genes shared between NOD and
NOD.Rag2/2 (Euclidean distance). Scale is in log2 fold change. (C)
Summarization of the top 1% of variance amongst our dataset as
determined by principal component analysis. For all summariza-
tion plots, we used Spearman’s rank correlation. Scales indicate
the range.
(TIF)
Figure S2 Identification of genes positively correlated with
diabetogenesis. (A) k-means clustering analysis of 21759 normal-
ized and curated genes in our dataset. K-means was performed
using Pearson’s correlation and 50 bin size at 100 iterations. The
line graphs in red represent 888 genes that had a positive
correlation throughout the time course of NOD diabetes but were
not upregulated from 2 wk to 6 wk in NOD.Rag2/2. These 888
genes were plotted in the heat map to the right using hierarchical
clustering (Euclidean distance). (B) Summarization of the 888
genes identified by Pearson’s correlation. Spearman’s rank
correlation was used to generate the plot. Scale represents the
range. (C) Venn diagrams showing the concordance of genes
identified by Pearson’s correlation compared to pairwise statistical
analysis (top) or principal component analysis (bottom).
(TIF)
Figure S3 Pearson’s correlation and ANOVA analysis demon-
strate 5 main patterns of immune gene upregulation during
diabetogenesis. (Left Column) Heat maps of hierarchically
clustered genes identified by Pearson’s correlation and ANOVA
analysis. (Right Column) Line graphs of normalized gene
expression throughout diabetogenesis. Black line represents the
normalized mean of expression for the cluster. The genes included
in both columns were identical. We tested these 5 major gene sets
that comprise 683 genes with significant changes across diabetes
development by ANOVA. Each cluster can be associated with
infiltration at distinct time points. Strikingly, three clusters were
strongly enriched in specific immune cell types: first, ‘‘4 wk
infiltration’’ cluster had overwhelming enrichment of macrophages
and dendritic cell types (i.e. myeloid cells). Second was the cluster
of genes that appeared at 8 wks and continued to grow on. This
cluster had enrichment in T-cells, B-cells, NK cells and DC types.
Finally, genes most strongly upregulated in newly diabetic NOD
mice, where extraordinarily enriched in various cytotoxic T-cell
types.
(TIF)
Figure S4 Expression levels of housekeeping, pancreas specific
genes, and Ptprc. Normalized expression of eight genes from
pancreatic microarrays. Bars represent the log2 transformed
mean+/2S.D. for 3–6 biological replicates per group.
(TIF)
Figure S5 Data modeling of transcriptional networks. The
analysis was performed as in Figure 6, except the (A) 4 wks, (B)
12 wks and (C) newly diabetic networks are shown.
(TIF)
Table S1 List of genes identified using Pearson’s correlation and
pairwise statistical analysis.
(XLSX)
Table S2 Leukocyte clusters used in the analysis.
(XLSX)
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